Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
Dren Bio
Allogene Therapeutics
University of Chicago
Ossium Health, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seattle Children's Hospital
Essen Biotech
Vironexis Biotherapeutics Inc.
Sheba Medical Center
Incyte Corporation
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
CRISPR Therapeutics
AVM Biotechnology Inc
CRISPR Therapeutics
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Princess Maxima Center for Pediatric Oncology
Bristol-Myers Squibb
Tianjin Medical University General Hospital
Affiliated Hospital to Academy of Military Medical Sciences
Beam Therapeutics Inc.
University of Sao Paulo
Takeda
Celgene
Altor BioScience
Columbia University
City of Hope Medical Center
University Hospital, Basel, Switzerland
University of Nebraska
Telios Pharma, Inc.
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Asana BioSciences
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Bristol-Myers Squibb
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Columbia University
TG Therapeutics, Inc.
Molecular Templates, Inc.
Bellicum Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center